You are here
Tyrosine Kinase Inhibitors Are Linked to Platelet Dysfunction in Patients with Chronic Myeloid Leukemia
This conclusion of a descriptive, cross-sectional study was reported at the 56th American Society of Hematology Annual Meeting and Exposition in San Francisco from December 6 – 9, 2014.
Wangsuekul Warit, MD, of Chiang Mai University, Chiang Mai, Thailand, explained that TKIs have become a standard of care for CML and possess a favorable safety profile. Dr. Warit said that a CML patient in his clinic who was taking imatinib developed a large retroperitoneal hematoma after oophorectomy. The patient’s platelet count and coagulogram were normal, suggesting platelet dysfunction. Platelet dysfunction has been reported with dasatinib, so the team decided to collect data on the prevalence of platelet dysfunction in patients with CML receiving TKIs in their clinic.